Annals of Oncology Advance Access published online on August 2, 2005
Annals of Oncology, doi:10.1093/annonc/mdi288
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Gynaecology and Department of Medicine, Breast and Gynaecological Oncology Medical Unit, Hôpitaux Universitaires de Genève, 30 Boulevard de la Cluse, 1211 Genève 14, Switzerland
* To whom correspondence should be addressed.
Editorial
Small randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?
H. Bonnefoi, E-mail: Herve.Bonnefoi{at}hcuge.ch
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A Di Leo, M Tanner, C Desmedt, M Paesmans, F Cardoso, V Durbecq, S Chan, T Perren, M Aapro, C Sotiriou, et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial Ann. Onc., June 1, 2007; 18(6): 997 - 1003. [Abstract] [Full Text] [PDF] |
||||
